Literature DB >> 20844859

[Node-positive prostate cancer. Value of radical prostatectomy].

A Heidenreich1, A J Schrader.   

Abstract

The current review article critically discusses the potential advantages and disadvantages of radical prostatectomy in patients with locally advanced lymph node-positive prostate cancer. It is the purpose of the manuscript to develop a therapeutic algorithm for management of these patients to achieve optimal oncological and functional results. Based on the data in the literature radical prostatectomy as part of a multimodality approach seems to be indicated in the following clinical scenario: limited intrapelvic lymph node metastasis without bulky disease; complete resectability of the primary cancer and metastases by extended radical prostatectomy and extended pelvic lymphadenectomy; inclusion of the patient in a multimodality approach; life expectancy > 10 years. In patients with extensive locally advanced PCA or large pelvic metastases, radical prostatectomy might be indicated to improve local cancer control and to prevent significant local and supravesical complications. In these cases, the indication for extensive surgery includes radical cystoprostatectomy and should be discussed in an interdisciplinary tumour board.

Entities:  

Mesh:

Year:  2010        PMID: 20844859     DOI: 10.1007/s00120-010-2399-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  37 in total

1.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

2.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

3.  Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).

Authors:  Fritz H Schröder; Karl-Heinz Kurth; Sophie D Fossa; Wytse Hoekstra; Peter P Karthaus; Linda De Prijck; Laurence Collette
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

4.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Authors:  John J Coen; Anthony L Zietman; Harjot Thakral; William U Shipley
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

5.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

7.  Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort.

Authors:  Gunnar Aus; Kerstin Nordenskjöld; David Robinson; Johan Rosell; Eberhard Varenhorst
Journal:  Eur Urol       Date:  2003-06       Impact factor: 20.096

8.  Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.

Authors:  Achim Fleischmann; Sylviane Schobinger; Martin Schumacher; George N Thalmann; Urs E Studer
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

9.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Authors:  Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

10.  Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy.

Authors:  A R Sgrignoli; P C Walsh; G D Steinberg; M S Steiner; J I Epstein
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.